Gastric Adenocarcinoma Clinical Trials

97 recruitingLast updated: June 17, 2026

There are 97 actively recruiting gastric adenocarcinoma clinical trials across 28 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Gastric Adenocarcinoma Trials at a Glance

97 actively recruiting trials for gastric adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 49 trials, with the heaviest enrollment activity in New York, Houston, and Nashville. Lead sponsors running gastric adenocarcinoma studies include Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse gastric adenocarcinoma trials by phase

Treatments under study

About Gastric Adenocarcinoma Clinical Trials

Looking for clinical trials for Gastric Adenocarcinoma? There are currently 63 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 97 trials

Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled372 locationsNCT06203600
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Advanced Solid TumorMetastatic Solid TumorEsophageal Squamous Cell Carcinoma+7 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 3

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.500 enrolled246 locationsNCT06901531
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 2

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaCLDN18.2 PositivePrimary Gastric Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.90 enrolled1 locationNCT07483567
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Colorectal, CancerHormone Receptor-Positive Breast CarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd174 enrolled3 locationsNCT07454642
Recruiting
Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled93 locationsNCT07043400
Recruiting
Phase 1

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Colorectal, CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+1 more
Dispatch Biotherapeutics66 enrolled3 locationsNCT07544589
Recruiting
Phase 2

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Not Applicable

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Stomach NeoplasmsGastric AdenocarcinomaLocally Advanced Gastric Cancer+1 more
Samsung Medical Center53 enrolled1 locationNCT07607119
Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 2

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Gastric AdenocarcinomaCarcinomatosis
M.D. Anderson Cancer Center30 enrolled1 locationNCT05977998
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Esophageal AdenocarcinomaGastric AdenocarcinomaHER2-negative+1 more
Gilead Sciences120 enrolled1 locationNCT07546812
Recruiting
Phase 2Phase 3

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Gastroesophageal Junction AdenocarcinomaPeritoneal CarcinomatosisGastric Adenocarcinoma
ECOG-ACRIN Cancer Research Group148 enrolled55 locationsNCT07001748
Recruiting
Not Applicable

Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma

Signet Ring Cell Gastric Adenocarcinoma
University Hospital, Lille314 enrolled1 locationNCT01717924
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell CarcinomaAdvanced Unresectable Gastric AdenocarcinomaAdvanced Gastroesophageal Adenocarcinoma
BeOne Medicines30 enrolled1 locationNCT07554521
Recruiting
Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled792 locationsNCT05677490
Recruiting
Phase 2Phase 3

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

Esophageal CancerEsophageal CarcinomaGastric (Stomach) Cancer+3 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)290 enrolled2 locationsNCT07000253
Recruiting
Phase 2

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

Gastric Adenocarcinoma
Banner Health30 enrolled1 locationNCT07178808